Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049320 · ClinicalTrials.gov registry record
Remifentanil for Sedation of Patients With Traumatic Brain Injury (TBI)
A clinical trial, sponsored by Joseph D. Tobias.
- Completed
- Registry status
- 38
- Enrollment target
NCT02049320: Completed study, sponsored by Joseph D. Tobias.
NCT02049320 is a clinical trial that has completed, run by Joseph D. Tobias. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02049320 has completed, sponsored by Joseph D. Tobias.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This is a descriptive retrospective study designed to measure the efficacy of remifentanil sedation and the ability to perform frequent neurological examinations of patients with traumatic brain injuries.
Primary Outcome
Sedation scores will be assessed.
Interventions
- DRUG Remifentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-05 |
What the finished NCT02049320 record still lists
NCT02049320 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Remifentanil is the first listed.
NCT02049320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02049320 about?
NCT02049320 is a clinical study titled "Remifentanil for Sedation of Patients With Traumatic Brain Injury (TBI)". This is a descriptive retrospective study designed to measure the efficacy of remifentanil sedation and the ability to perform frequent neurological examinations of patients with traumatic brain injuries.
What is the current status of trial NCT02049320?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2013-07. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02049320?
The interventions under investigation include: Remifentanil (DRUG).
Who is sponsoring clinical trial NCT02049320?
This trial is sponsored by Joseph D. Tobias, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia